Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Oncology
Oncology — Sep 7 – Sep 11, 2026 (Wk 37): Oncology Theme: Earnings, Analyst Targets, and Pipeline Updates Drive Activity →This week in oncology saw a mix of company-specific news, including earnings reports and analyst target adjustments, alongside updates on drug pipelines. These developments highlight the ongoing focus on clinical progress and financial performance within the…
AAPG
Valuation N/A
ASCENTAGE PHARMA GROUP INTERNATIONAL
Price$16.00
Model IV—
P/IV—
Limited data — see page
ABBV
Overvalued
AbbVie Inc.
Price$263.04
Model IV$208.02
P/IV1.24
Premium +26%
Return to IV: -20.9%
Market implies +6.9%/yr
vs model +4.5% · in line
ACET
Valuation N/A
Adicet Bio, Inc.
Price$9.52
Model IV—
P/IV—
Limited data — see page
ACRV
Valuation N/A
Acrivon Therapeutics, Inc.
Price$2.00
Model IV—
P/IV—
Limited data — see page
ACTU
Valuation N/A
ACTUATE THERAPEUTICS, INC.
Price$1.07
Model IV—
P/IV—
Limited data — see page
ADAG
Valuation N/A
Adagene Inc.
Price$3.40
Model IV—
P/IV—
Market implies +45.1%/yr
vs model +2.0% · above model
ADCT
Valuation N/A
ADC Therapeutics SA
Price$1.11
Model IV—
P/IV—
Market implies +11.9%/yr
vs model +15.0% · below model
AEMD
Valuation N/A
AETHLON MEDICAL INC
Price$1.54
Model IV—
P/IV—
Market implies +15.4%/yr
vs model +15.0% · in line
AGEN
Valuation N/A
AGENUS INC
Price$7.13
Model IV—
P/IV—
Market implies +48.5%/yr
vs model +2.0% · above model
AGIO
Valuation N/A
AGIOS PHARMACEUTICALS, INC.
Price$32.81
Model IV—
P/IV—
Market implies +37.7%/yr
vs model +15.0% · above model
AIM
Valuation N/A
AIM ImmunoTech Inc.
Price$0.22
Model IV—
P/IV—
Market implies +14.1%/yr
vs model +2.0% · above model
AKTS
Valuation N/A
Aktis Oncology, Inc.
Price$23.17
Model IV—
P/IV—
Limited data — see page
ALKS
Deeply undervalued
Alkermes plc.
Price$45.97
Model IV$45.18
P/IV0.56
Premium +2%
Return to IV: -1.7%
Market implies +6.1%/yr
vs model +7.1% · in line
ALLO
Valuation N/A
Allogene Therapeutics, Inc.
Price$1.72
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +15.0% · above model
ALLR
Valuation N/A
Allarity Therapeutics, Inc.
Price$1.22
Model IV—
P/IV—
Market implies +64.5%/yr
vs model +15.0% · above model
ALXO
Valuation N/A
ALX ONCOLOGY HOLDINGS INC
Price$1.89
Model IV—
P/IV—
Limited data — see page
AMGN
Undervalued
AMGEN INC
Price$377.35
Model IV$452.91
P/IV0.74
Discount 17%
Return to IV: +20.0%
Market implies +6.1%/yr
vs model +10.7% · below model
AMS
Deeply undervalued
AMERICAN SHARED HOSPITAL SERVICES
Price$1.47
Model IV$12.41
P/IV0.12
Discount 88%
Return to IV: +741.3%
Market implies -50.0%/yr
vs model +12.4% · below model
ANGO
Deeply overvalued
ANGIODYNAMICS INC
Price$15.68
Model IV$6.05
P/IV1.90
Premium +159%
Return to IV: -61.4%
Market implies +12.1%/yr
vs model +2.0% · above model
ANIX
Valuation N/A
Anixa Biosciences Inc
Price$2.76
Model IV—
P/IV—
Limited data — see page
ANL
Valuation N/A
Adlai Nortye Ltd.
Price$15.21
Model IV—
P/IV—
Limited data — see page
APLM
Valuation N/A
Apollomics Inc.
Price$23.21
Model IV—
P/IV—
Limited data — see page
APLMW
Valuation N/A
Apollomics Inc.
Price$0.01
Model IV—
P/IV—
Limited data — see page
APM
Valuation N/A
Aptorum Group Ltd
Price$8.41
Model IV—
P/IV—
Market implies +61.6%/yr
vs model +15.0% · above model
APRE
Valuation N/A
Aprea Therapeutics, Inc.
Price$0.77
Model IV—
P/IV—
Limited data — see page
APVO
Valuation N/A
Aptevo Therapeutics Inc.
Price$1.82
Model IV—
P/IV—
Market implies -18.9%/yr
vs model +15.0% · below model
ARAY
Valuation N/A
ACCURAY INC
Price$0.25
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +3.7% · below model
ARTL
Valuation N/A
ARTELO BIOSCIENCES, INC.
Price$5.43
Model IV—
P/IV—
Limited data — see page
ARTV
Valuation N/A
Artiva Biotherapeutics, Inc.
Price$8.91
Model IV—
P/IV—
Market implies +116.4%/yr
vs model +15.0% · above model
ARVN
Deeply undervalued
ARVINAS, INC.
Price$8.45
Model IV$26.34
P/IV0.34
Discount 68%
Return to IV: +211.7%
Market implies -20.1%/yr
vs model +48.8% · below model
ASND
Valuation N/A
Ascendis Pharma A/S
Price$263.52
Model IV—
P/IV—
Limited data — see page
ATNM
Valuation N/A
Actinium Pharmaceuticals, Inc.
Price$1.28
Model IV—
P/IV—
Market implies +89.9%/yr
vs model +2.0% · above model
ATOS
Valuation N/A
ATOSSA THERAPEUTICS, INC.
Price$2.48
Model IV—
P/IV—
Limited data — see page
ATRA
Fairly valued
Atara Biotherapeutics, Inc.
Price$9.25
Model IV$9.66
P/IV1.09
Discount 4%
Return to IV: +4.5%
Market implies -3.3%/yr
vs model +15.0% · below model
AUNA
Valuation N/A
AUNA S.A.
Price$5.17
Model IV—
P/IV—
Limited data — see page
AURA
Valuation N/A
Aura Biosciences, Inc.
Price$7.00
Model IV—
P/IV—
Limited data — see page
AUTL
Valuation N/A
Autolus Therapeutics plc
Price$1.94
Model IV—
P/IV—
Market implies +34.2%/yr
vs model +15.0% · above model
AVBP
Valuation N/A
ArriVent BioPharma, Inc.
Price$28.57
Model IV—
P/IV—
Limited data — see page
AVTX
Valuation N/A
Avalo Therapeutics, Inc.
Price$16.12
Model IV—
P/IV—
Market implies +142.3%/yr
vs model +2.0% · above model
AZN
Valuation N/A
ASTRAZENECA PLC
Price$160.17
Model IV—
P/IV—
Limited data — see page
BBIO
Deeply overvalued
BridgeBio Pharma, Inc.
Price$72.44
Model IV$17.72
P/IV3.74
Premium +309%
Return to IV: -75.5%
Market implies +19.3%/yr
vs model +50.0% · below model
BBOT
Valuation N/A
BridgeBio Oncology Therapeutics, Inc.
Price$4.95
Model IV—
P/IV—
Limited data — see page
BCAB
Valuation N/A
BioAtla, Inc.
Price$1.50
Model IV—
P/IV—
Market implies +65.3%/yr
vs model +15.0% · above model
BCAX
Valuation N/A
Bicara Therapeutics Inc.
Price$22.81
Model IV—
P/IV—
Limited data — see page
BCTX
Valuation N/A
BriaCell Therapeutics Corp.
Price$3.63
Model IV—
P/IV—
Limited data — see page
BCTXL
Valuation N/A
BriaCell Therapeutics Corp.
Price$0.95
Model IV—
P/IV—
Limited data — see page
BCTXZ
Valuation N/A
BriaCell Therapeutics Corp.
Price$0.14
Model IV—
P/IV—
Limited data — see page
BDRX
Valuation N/A
Biodexa Pharmaceuticals Plc
Price$1.33
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +15.0% · above model
BDSX
Fairly valued
BIODESIX INC
Price$26.97
Model IV$16.65
P/IV0.98
Premium +62%
Return to IV: -38.2%
Market implies +1.2%/yr
vs model +12.9% · below model
BDTX
Deeply undervalued
Black Diamond Therapeutics, Inc.
Price$1.98
Model IV$4.09
P/IV0.54
Discount 52%
Return to IV: +106.5%
Market implies -6.3%/yr
vs model +10.0% · below model
BEAM
Valuation N/A
Beam Therapeutics Inc.
Price$23.99
Model IV—
P/IV—
Market implies +43.2%/yr
vs model +28.1% · above model
BFRI
Valuation N/A
Biofrontera Inc.
Price$1.55
Model IV—
P/IV—
Market implies -11.3%/yr
vs model +14.8% · below model
BFRIW
Valuation N/A
Biofrontera Inc.
Price$0.02
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +14.7% · below model
BIAF
Valuation N/A
bioAffinity Technologies, Inc.
Price$7.95
Model IV—
P/IV—
Market implies +81.5%/yr
vs model +15.0% · above model
BLLN
Overvalued
BillionToOne, Inc.
Price$98.77
Model IV$83.33
P/IV1.19
Premium +19%
Return to IV: -15.6%
Market implies +4.4%/yr
vs model +50.0% · below model
BLRX
Valuation N/A
BioLineRx Ltd.
Price$2.51
Model IV—
P/IV—
Limited data — see page
BMEA
Valuation N/A
Biomea Fusion, Inc.
Price$1.74
Model IV—
P/IV—
Limited data — see page
BMY
Deeply undervalued
BRISTOL MYERS SQUIBB CO
Price$63.64
Model IV$174.33
P/IV0.33
Discount 63%
Return to IV: +173.9%
Market implies -7.4%/yr
vs model +6.1% · below model
BNR
Valuation N/A
Burning Rock Biotech Ltd
Price$12.28
Model IV—
P/IV—
Limited data — see page
BNTX
Valuation N/A
BioNTech SE
Price$96.73
Model IV—
P/IV—
Limited data — see page